Hologic Inc HOLX
We take great care to ensure that the data presented and summarized in this overview for HOLOGIC INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HOLX
View all-
Vanguard Group Inc Valley Forge, PA26.8MShares$2.18 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY23.1MShares$1.88 Billion0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD22.5MShares$1.82 Billion1.05% of portfolio
-
State Street Corp Boston, MA10.3MShares$839 Million0.03% of portfolio
-
Morgan Stanley New York, NY7.81MShares$635 Million0.05% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.88MShares$477 Million0.05% of portfolio
-
Victory Capital Management Inc5.66MShares$460 Million0.44% of portfolio
-
Geode Capital Management, LLC Boston, MA5.57MShares$453 Million0.04% of portfolio
-
Macquarie Group LTD Australia, C33.67MShares$298 Million0.32% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.49MShares$284 Million0.07% of portfolio
Latest Institutional Activity in HOLX
Top Purchases
Top Sells
About HOLX
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Insider Transactions at HOLX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 29
2024
|
Karleen Marie Oberton Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
52,679
-38.53%
|
$4,214,320
$80.56 P/Share
|
Aug 29
2024
|
Karleen Marie Oberton Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,805
+10.7%
|
$1,312,200
$40.91 P/Share
|
Aug 06
2024
|
Brandon Schnittker Div. President, GYN Surgical |
SELL
Open market or private sale
|
Direct |
476
-11.3%
|
$39,508
$83.11 P/Share
|
Aug 01
2024
|
Benjamin Jordan Cohn Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,093
-32.71%
|
$412,533
$81.99 P/Share
|
Jul 30
2024
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
44,039
-1.24%
|
$3,567,159
$81.45 P/Share
|
Jul 30
2024
|
Stephen P Macmillan Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,039
+3.54%
|
$1,145,014
$26.21 P/Share
|
Jul 17
2024
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
3,672
-0.32%
|
$293,760
$80.13 P/Share
|
Jul 17
2024
|
Stephen P Macmillan Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,672
+0.32%
|
$95,472
$26.21 P/Share
|
Jul 17
2024
|
Christiana Stamoulis Director |
SELL
Open market or private sale
|
Direct |
9,039
-16.58%
|
$714,081
$79.5 P/Share
|
Jul 17
2024
|
Christiana Stamoulis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,039
+14.22%
|
$235,014
$26.74 P/Share
|
May 31
2024
|
Brandon Schnittker Div. President, GYN Surgical |
SELL
Payment of exercise price or tax liability
|
Direct |
67
-1.57%
|
$4,891
$73.78 P/Share
|
May 23
2024
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Bona fide gift
|
Direct |
57,875
-4.76%
|
-
|
Apr 22
2024
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Bona fide gift
|
Direct |
12,000
-0.98%
|
-
|
Apr 19
2024
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Bona fide gift
|
Direct |
12,000
-0.97%
|
-
|
Mar 14
2024
|
Scott T Garrett Director |
SELL
Open market or private sale
|
Direct |
16,441
-25.27%
|
$1,233,075
$75.5 P/Share
|
Mar 14
2024
|
Scott T Garrett Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,441
+11.89%
|
$509,671
$31.39 P/Share
|
Mar 08
2024
|
Charles J Dockendorff Director |
SELL
Open market or private sale
|
Direct |
1,465
-48.24%
|
$111,340
$76.21 P/Share
|
Mar 08
2024
|
Sally Crawford Director |
SELL
Open market or private sale
|
Direct |
9,039
-6.37%
|
$686,964
$76.4 P/Share
|
Mar 08
2024
|
Sally Crawford Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,039
+5.99%
|
$235,014
$26.74 P/Share
|
Mar 07
2024
|
Charles J Dockendorff Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,572
+34.11%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 134K shares |
---|---|
Exercise of conversion of derivative security | 170K shares |
Open market or private sale | 238K shares |
---|---|
Payment of exercise price or tax liability | 107K shares |
Bona fide gift | 81.9K shares |